Role of O-(2-18F-Fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma

Journal of Nuclear Medicine

Volumn 54, Issue 12, 2013, Pages 2046-2054

  Galldiks, Norbert ^a,b   Stoffels, Gabriele ^a,c   Ruge, Maximilian I ^b   Rapp, Marion ^d   Sabel, Michael ^d   Reifenberger, Guido ^d,e   Erdem, Zuhal ^a   Shah, Nadim J ^a,c   Fink, Gereon R ^a,b   Coenen, Heinz H ^a,c   Langen, Karl Josef ^a,c,f  

^a FORSCHUNGSZENTRUM JÜLICH   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c Julich Aachen Research Alliance JARA   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Time to peak

Indexed keywords

O (2 FLUOROETHYL)TYROSINE F 18; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG; O-(2-FLUOROETHYL)TYROSINE; TYROSINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; O (2 FLUOROETHYL)TYROSINE;

ADULT; ARTICLE; ASTROCYTOMA; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CHILD; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CORRELATIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EPENDYMOMA; FEMALE; GLIOBLASTOMA; GLIOMA; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT TRANSFORMATION; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; SCHOOL CHILD; TUMOR BIOPSY; YOUNG ADULT; ADOLESCENT; ANALOGS AND DERIVATIVES; DIAGNOSTIC USE; DISEASE COURSE; KINETICS; METABOLISM; PATHOLOGY; REGRESSION ANALYSIS; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL; 18F-FET KINETICS; REPEATED 18F-FET PET IMAGING; TIME TO PEAK;

ADOLESCENT; ADULT; BIOLOGICAL TRANSPORT; CHILD; DISEASE PROGRESSION; FEMALE; GLIOMA; HUMANS; KINETICS; MALE; MIDDLE AGED; NEOPLASM GRADING; POSITRON-EMISSION TOMOGRAPHY; REGRESSION ANALYSIS; TYROSINE; YOUNG ADULT;

18F-FET KINETICS; REPEATED 18F-FET PET IMAGING; TIME TO PEAK;

EID: 84893375253     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.123836     Document Type: Article

References (26)

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97-109.
2. Grier JT, Batchelor T. Low-grade gliomas in adults. Oncologist. 2006;11:681-693.
3. Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA. 2012;308:1881-1888.
4. Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANOTask Force. Eur J Neurol. 2010;17:1124-1133.
5. McCormack BM, Miller DC, Budzilovich GN, Voorhees GJ, Ransohoff J. Treatment and survival of low-grade astrocytoma in adults: 1977-1988. Neurosurgery. 1992;31:636-642.
6. Chaichana KL, McGirt MJ, Laterra J, Olivi A, Quinones-Hinojosa A. Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. J Neurosurg. 2010;112:10-17.
7. Ginsberg LE, Fuller GN, Hashmi M, Leeds NE, Schomer DF. The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol. 1998;49:436-440.
8. Scott JN, Brasher PM, Sevick RJ, Rewcastle NB, Forsyth PA. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology. 2002;59:947-949.
9. Perez-Cruet MJ, Adelman L, Anderson M, Roth PA, Ritter AM, Saris SC. CTguided stereotactic biopsy of nonenhancing brain lesions. Stereotact Funct Neurosurg. 1993;61:105-117.
10. Galldiks N, Kracht LW, Dunkl V, et al. Imaging of non- or very subtle contrastenhancing malignant gliomas with [11C]-methionine positron emission tomography. Mol Imaging. 2011;10:453-459.
11. Ullrich RT, Kracht L, Brunn A, et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Med. 2009;50:1962-1968.
12. Weckesser M, Langen KJ, Rickert CH, et al. O-(2-[18F]fluorethyl)-L- tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging. 2005;32:422-429.
13. Langen KJ, Hamacher K, Weckesser M, et al. O-(2-[18F]fluoroethyl)-L- tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol. 2006;33:287-294.
14. Wester HJ, Herz M, Weber W, et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med. 1999;40:205-212.
15. Hamacher K, Coenen HH. Efficient routine production of the 18F-labelled amino acid O-2-18F fluoroethyl-L-tyrosine. Appl Radiat Isot. 2002;57:853-856.
16. Calcagni ML, Galli G, Giordano A, et al. Dynamic O-(2-[18F]fluoroethyl)- Ltyrosine (F-18 FET) PET for glioma grading: assessment of individual probability of malignancy. Clin Nucl Med. 2011;36:841-847.
17. Pöpperl G, Kreth FW, Herms J, et al. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med. 2006;47:393-403.
18. Jansen NL, Graute V, Armbruster L, et al. MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging. 2012;39:1021-1029.
19. Macdonald DR, Cascino TL, Schold SC Jr., Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.
20. Langen KJ, Bartenstein P, Boecker H, et al. German guidelines for brain tumour imaging by PET and SPECT using labelled amino acids [in German]. Nuklearmedizin. 2011;50:167-173.
21. Pauleit D, Floeth F, Hamacher K, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain. 2005;128:678-687.
22. Moulin-Romsée G, D'Hondt E, de Groot T, et al. Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11C-methionine? Eur J Nucl Med Mol Imaging. 2007;34:2082-2087.
23. Pöpperl G, Kreth FW, Mehrkens JH, et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging. 2007;34:1933-1942.
24. Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic 18FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro-oncol. 2011;13:307-316.
25. Jansen NL, Schwartz C, Graute V, et al. Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [18F]FET-PET imaging in intracranial WHO grade II and III gliomas. Neuro-oncol. 2012;14:1473-1480.
26. Crocetti E, Trama A, Stiller C, et al. Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer. 2012;48:1532-1542.